ES2885423T3 - Procedimientos para la expansión o el empobrecimiento de células T reguladoras - Google Patents

Procedimientos para la expansión o el empobrecimiento de células T reguladoras Download PDF

Info

Publication number
ES2885423T3
ES2885423T3 ES14748807T ES14748807T ES2885423T3 ES 2885423 T3 ES2885423 T3 ES 2885423T3 ES 14748807 T ES14748807 T ES 14748807T ES 14748807 T ES14748807 T ES 14748807T ES 2885423 T3 ES2885423 T3 ES 2885423T3
Authority
ES
Spain
Prior art keywords
cancer
cells
virus
tnfr2
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14748807T
Other languages
English (en)
Spanish (es)
Inventor
Denise Faustman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Application granted granted Critical
Publication of ES2885423T3 publication Critical patent/ES2885423T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/04—Immunosuppressors, e.g. cyclosporin, tacrolimus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
ES14748807T 2013-02-07 2014-02-06 Procedimientos para la expansión o el empobrecimiento de células T reguladoras Active ES2885423T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361762136P 2013-02-07 2013-02-07
US201361763217P 2013-02-11 2013-02-11
PCT/US2014/015101 WO2014124134A1 (en) 2013-02-07 2014-02-06 Methods for expansion or depletion of t-regulatory cells

Publications (1)

Publication Number Publication Date
ES2885423T3 true ES2885423T3 (es) 2021-12-13

Family

ID=51300130

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14748807T Active ES2885423T3 (es) 2013-02-07 2014-02-06 Procedimientos para la expansión o el empobrecimiento de células T reguladoras

Country Status (9)

Country Link
US (4) US9821010B2 (enExample)
EP (2) EP3936137A1 (enExample)
JP (5) JP6367836B2 (enExample)
DK (1) DK2953634T3 (enExample)
ES (1) ES2885423T3 (enExample)
HR (1) HRP20211353T1 (enExample)
PL (1) PL2953634T3 (enExample)
PT (1) PT2953634T (enExample)
WO (1) WO2014124134A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6031552A (en) * 1994-11-18 2000-02-29 Heidelberger Druckmaschinen Ag Printing device with patterned recording surface
DK2953634T3 (da) 2013-02-07 2021-08-30 Massachusetts Gen Hospital Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
US12174188B2 (en) 2013-10-17 2024-12-24 The General Hospital Corporation Methods of identifying subjects responsive to treatment for type 1 diabetes and compositions for treating the same
US10500273B2 (en) * 2015-03-02 2019-12-10 180 Therapeutics Lp Method of treating a localized fibrotic disorder using an IL-33 antagonist
ES2948133T3 (es) 2015-04-17 2023-08-31 Novartis Ag Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
HRP20231392T1 (hr) * 2015-05-15 2024-04-26 The General Hospital Corporation Antagonistička protutijela na superobitelj receptora za faktor tumorske nekroze
TWI859112B (zh) 2015-07-21 2024-10-21 瑞士商諾華公司 改良免疫細胞之功效及擴展之方法
US20190135929A1 (en) * 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
EP3355914B1 (en) 2015-09-29 2024-03-06 The General Hospital Corporation A composition comprising bcg for reducing cholesterol.
AU2016344745A1 (en) * 2015-10-28 2018-05-17 Life Technologies As Selective expansion of different subpopulations of T cells by the alteration of cell surfacing signals and signal ratio
CA3004830A1 (en) * 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
CA3006432A1 (en) 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
TW201726744A (zh) * 2016-01-11 2017-08-01 奧托德里克有限公司 用於檢測奧美沙坦(olmesartan)及改善治療高血壓之遵從性的組成物、裝置及方法
EP3455262A4 (en) * 2016-05-13 2020-04-08 The General Hospital Corporation ANTAGONISTIC ANTI-TUMOR NECROSE FACTOR RECEPTOR SUPER FAMILY ANTIBODIES
ES2941972T3 (es) 2016-06-22 2023-05-29 Univ Paris Val De Marne Prevención o tratamiento de la recaída de neoplasias malignas hematológicas mediante un antagonista de TNFR2
JP7054209B2 (ja) * 2016-11-21 2022-04-13 国立研究開発法人医薬基盤・健康・栄養研究所 エピトープ均質化抗体パネル、ならびにその作製方法および利用
CN110621321B (zh) 2017-03-15 2024-06-21 浩康生物系统公司 用于造血干细胞移植的组合物和方法
SG11201907434RA (en) 2017-03-22 2019-10-30 Novartis Ag Compositions and methods for immunooncology
AU2018268970B2 (en) 2017-05-19 2024-12-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
WO2019096787A1 (en) * 2017-11-14 2019-05-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Regulatory t cells genetically modified for the lymphotoxin alpha gene and uses thereof
US12233094B2 (en) * 2017-11-29 2025-02-25 Spinalcyte, Llc Interaction of fibroblasts and immune cells for activation and uses thereof
WO2020061210A1 (en) * 2018-09-18 2020-03-26 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
CA3117864A1 (en) * 2018-11-01 2020-05-07 Bioinvent International Ab Novel antagonistic anti tnfr2 antibody molecules
WO2020089473A2 (en) * 2018-11-01 2020-05-07 Bioinvent International Ab Novel agonistic antibody molecules
CN109609616B (zh) * 2018-11-05 2021-12-07 复旦大学附属华山医院 Hla-a*02:01和hla-c*01:02在丹参酮所致药疹中的用途
WO2020102739A1 (en) * 2018-11-15 2020-05-22 The General Hospital Corporation Agonistic tumor necrosis factor receptor superfamily polypeptides
CA3131953A1 (en) 2019-03-01 2020-09-10 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
CN109846863B (zh) * 2019-03-12 2021-09-21 成都金瑞基业生物科技有限公司 和厚朴酚的用途
CN110179790A (zh) * 2019-07-02 2019-08-30 广西医科大学 一种抑制肝星状细胞活化药物的制备及应用
US20220372154A1 (en) * 2019-09-17 2022-11-24 Apexigen, Inc. Anti-tnfr2 antibodies and methods of use
CN110693907A (zh) * 2019-11-07 2020-01-17 南通大学 调节性T细胞在制备治疗或预防Zika病毒感染所致不良妊娠药物方面的应用
CN110974818A (zh) * 2019-12-31 2020-04-10 中国药科大学 咖啡酸苯乙酯在制备肝再生药物中的应用
CA3166898A1 (en) * 2020-01-06 2021-07-15 Hifibio (Hk) Limited Anti-tnfr2 antibody and uses thereof
EP4130033A4 (en) * 2020-03-30 2024-08-07 National Institutes of Biomedical Innovation, Health and Nutrition EPITOPE REGION BYPASSING BIPARATOPIC ANTIBODY AND PRODUCTION METHOD THEREOF
WO2021249542A1 (en) * 2020-06-12 2021-12-16 Nanjing Leads Biolabs Co., Ltd. Antibodies binding tnfr2 and uses thereof
CN113825832B (zh) * 2020-07-28 2024-12-13 浙江大学 一种体外诱导CD4+Foxp3+CD69+Treg的扩增方法及其用途
AU2021332460A1 (en) 2020-08-27 2023-04-06 Enosi Therapeutics Corporation Methods and compositions to treat autoimmune diseases and cancer
CN111920802B (zh) * 2020-09-11 2024-01-23 华侨大学 穿心莲内酯在制备防治成人t细胞白血病药物的应用
CN115925929A (zh) 2021-09-22 2023-04-07 上海康岱生物医药技术股份有限公司 抗tnfr2单克隆抗体及其应用
WO2025049818A1 (en) 2023-08-29 2025-03-06 Enosi Therapeutics Corporation Tnfr1 antagonists lacking agonist activity and uses thereof

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4309418A (en) 1980-03-25 1982-01-05 Sloan-Kettering Research Institute For Cancer Anti-tumor agent from human serum and process
SE8204382L (sv) 1981-07-21 1983-01-22 Hayashibara Biochem Lab Sett att framstella malcellysfaktor och anvendning derav
US4457916A (en) 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5288852A (en) 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
EP0155549B1 (en) 1984-03-06 1991-03-20 Dainippon Pharmaceutical Co., Ltd. Dna encoding human tumor necrosis factor and human tumor necrosis factor polypeptide
US4879226A (en) 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
DE3423234A1 (de) 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
GR851626B (enExample) 1984-07-05 1985-11-26 Genentech Inc
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4677064A (en) 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
DE3581730D1 (de) 1984-10-15 1991-03-14 Cetus Corp Menschlicher tumornekrosisfaktor.
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
AU601675B2 (en) 1984-12-21 1990-09-20 Biogen, Inc. Purification, production and use of tumor necrosis factors
US4681760A (en) 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
US5059530A (en) 1985-09-30 1991-10-22 Suntory Ltd. Expression vector for human TNF
US6150090A (en) 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
DE3750056T2 (de) 1986-06-20 1995-04-06 Dainippon Pharmaceutical Co Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS.
US5002876A (en) 1986-09-22 1991-03-26 Phillips Petroleum Company Yeast production of human tumor necrosis factor
US4985241A (en) 1986-11-21 1991-01-15 Cetus Corporation Therapeutic combination of free-radical scavenger and tumor necrosis factor
US4963354A (en) 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
AU1346488A (en) 1987-02-26 1988-09-26 Cetus Corporation Arginine-depleted human tumor necrosis factor
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5215743A (en) 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
JPH0797997B2 (ja) 1988-04-28 1995-10-25 帝人株式会社 新規生理活性ポリペプチド
US5370870A (en) 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
US5283058A (en) 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
US5593698A (en) 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
CA2055168A1 (en) 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
EP1298203A3 (en) 1991-08-02 2004-01-21 FAUSTMAN, Denise L. Diagnosis and treatment of autoimmune diseases
US6984380B1 (en) 1991-08-02 2006-01-10 Denise L. Faustman Treatment of diseases involving faulty MHC class I antigen complex presentation
US5139481A (en) 1991-08-07 1992-08-18 The General Hospital Corporation Treatment for type II diabetes
US5843425A (en) 1992-02-19 1998-12-01 The General Hospital Corporation Transplantation and graft-versus-host-disease
CZ283533B6 (cs) 1992-04-02 1998-04-15 F. Hoffmann-La Roche Ag TNF - muteiny a způsob jejich výroby
JP3750819B2 (ja) 1992-04-23 2006-03-01 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ Ｃ−ｋｉｔ受容体に対するリガンド及びその使用法
US5939532A (en) 1993-09-07 1999-08-17 Kyowa Hakko Kogyo Co., Ltd Humanized antibodies to ganglioside GM2
WO1994009137A1 (en) 1992-10-15 1994-04-28 Genentech, Inc. Antibodies against type 2 tumor necrosis factor receptor
US5843452A (en) 1992-11-09 1998-12-01 Pharmagenesis, Inc. Immunotherapy composition and method
EP0612529B1 (en) 1993-01-22 2000-04-05 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Therapeutic agent for NIDDM
WO1995003812A1 (de) * 1993-07-29 1995-02-09 Bernhard Heising T-lymphozyten enthaltende pharmazeutische zusammensetzung zur behandlung von infektionen
US5728385A (en) 1993-08-12 1998-03-17 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US5874301A (en) 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US6056952A (en) 1995-08-30 2000-05-02 The United States Of America As Represented By The Department Of Health And Human Services Selective elimination of T cells that recognize specific preselected targets
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US5874306A (en) 1996-12-12 1999-02-23 The Regents Of The University Of California Culturing human pancreatic endocrine cells in medium containing extracellular matrix from human bladder carcinoma cells
AU6241698A (en) 1997-01-21 1998-08-07 Human Genome Sciences, Inc. Tace-like and matrilysin-like polypeptides
US6177076B1 (en) 1997-12-09 2001-01-23 Thomas Jefferson University Method of treating bladder cancer with wild type vaccinia virus
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6284879B1 (en) 1998-04-16 2001-09-04 The General Hospital Corporation Transport associated protein splice variants
US6165737A (en) 1998-04-16 2000-12-26 The University Of Texas System Board Of Regents DNA fragmentation factor involved in apoptosis
JP2002512203A (ja) 1998-04-17 2002-04-23 ザ ユニバーシティ オブ バーモント アンド ステイト アグリカルチュラル カレッジ 疾患における代謝的相互作用に関連する方法および製品
JP2002515459A (ja) 1998-05-18 2002-05-28 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ 喘息および他のアレルギー性症状を治療するための方法およびｔｎｆ−ｒｉｉ（ｐ７５）アゴニストを含む組成物の使用
US7485293B1 (en) 1999-02-18 2009-02-03 Faustman Denise L Method for inhibiting transplant rejection
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
JP3589912B2 (ja) 1999-09-03 2004-11-17 泰久 福井 ホスファチジルイノシトール−３，４−二リン酸を認識するモノクローナル抗体
CN100475953C (zh) 1999-12-06 2009-04-08 通用医疗公司 胰腺干细胞
CA2394536A1 (en) 1999-12-16 2001-06-21 Amgen Inc. Tnfr/opg-like molecules and uses thereof
US6414218B1 (en) 2000-01-18 2002-07-02 The General Hospital Corporation Mouse model for rheumatoid arthritis
JP2003534022A (ja) 2000-05-26 2003-11-18 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療に有用な抗−ｒａｎｋリガンドモノクローナル抗体
WO2002026819A2 (en) 2000-09-26 2002-04-04 Roger Williams Hospital Recombinant bcg vaccines for the prevention and treatment of cancer
US20040031066A9 (en) 2001-01-18 2004-02-12 Faustman Denise L. Mouse model for rheumatoid arthritis
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
WO2004045376A2 (en) 2002-11-15 2004-06-03 The General Hospital Corporation Screening methods to identify treatments for autoimmune disease
US7510877B2 (en) 2003-09-26 2009-03-31 The Regents Of The University Of Michigan Hematopoietic stem cell identification and isolation
JPWO2005035578A1 (ja) 2003-10-09 2007-11-22 協和醗酵工業株式会社 ガングリオシドｇｍ２に特異的に結合する抗体組成物
US8563308B2 (en) 2004-03-10 2013-10-22 The Rockefeller University Culture-expanded T suppressor cells and methods of use thereof
EP2295588B1 (en) * 2004-05-27 2018-03-07 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses thefor
CN101084014A (zh) 2004-10-08 2007-12-05 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
US20080102054A1 (en) 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
WO2006109044A2 (en) * 2005-04-11 2006-10-19 Yale University Selective modulation of tumour necrosis factor receptors in therapy
EP2107115A1 (en) 2007-01-24 2009-10-07 Kyowa Hakko Kirin Co., Ltd. Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
WO2008157394A2 (en) 2007-06-13 2008-12-24 La Jolla Institute For Allergy And Immunology Regulatory t cells and methods of making and using same
US8900816B2 (en) 2007-07-19 2014-12-02 Duke University Assay for anti-EGFRvIII antibodies
EP2280997A2 (en) * 2008-04-18 2011-02-09 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
WO2010120374A2 (en) * 2009-04-17 2010-10-21 New York University Peptides targeting tnf family receptors and antagonizing tnf action, compositions, methods and uses thereof
WO2010124259A1 (en) 2009-04-24 2010-10-28 Centre Hospitalier Universitaire Sainte-Justine Allosteramers for tnf receptors and uses thereof
AU2010241701A1 (en) 2009-04-28 2011-10-13 Boehringer Ingelheim International Gmbh Ex-vivo treatment of immunological disorders with PKC-theta inhibitors
WO2010131704A1 (ja) 2009-05-13 2010-11-18 塩野義製薬株式会社 内臓脂肪型肥満の検査薬およびその利用
US8653242B2 (en) 2010-03-01 2014-02-18 Lostam Pharmaceuticals Ltd. Therapeutic antibodies against flagellated Pseudomonas aeruginosa
DK2542590T4 (da) 2010-03-05 2020-07-13 Univ Johns Hopkins Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner
EP2571577A1 (en) 2010-05-17 2013-03-27 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
US8859739B2 (en) 2010-09-16 2014-10-14 Baliopharm Ag Anti-huTNFR1 antibody and methods of use thereof for treatment
US20140121123A1 (en) 2010-10-29 2014-05-01 Kevin Caili Wang Methods for diversifying antibodies, antibodies derived therefrom and uses thereof
EP2468764A1 (en) 2010-12-24 2012-06-27 Rijksuniversiteit te Groningen TNF family ligand variants
WO2012122464A1 (en) * 2011-03-10 2012-09-13 New York University Methods and compositions for modulating tnf/tnfr signaling
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
US20150110794A1 (en) 2012-04-30 2015-04-23 Cell Signaling Technology, Inc. Anti-Human Cytomegalovirus Antibodies And Use Thereof
EP2875619B1 (en) 2012-07-18 2016-09-14 Kyocera Corporation Interference managment of device-to-device communication in a cellular communication system
DK2953634T3 (da) 2013-02-07 2021-08-30 Massachusetts Gen Hospital Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
CA2943167A1 (en) 2014-03-24 2015-10-01 University Of Southampton Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof
CA2957146A1 (en) 2014-08-12 2016-02-18 Alligator Bioscience Ab Combination therapies with anti cd40 antibodies
US9172855B1 (en) 2014-08-28 2015-10-27 Avigilon Corporation Pendant housing for a camera
HRP20231392T1 (hr) 2015-05-15 2024-04-26 The General Hospital Corporation Antagonistička protutijela na superobitelj receptora za faktor tumorske nekroze
US20190135929A1 (en) 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
CA3004830A1 (en) 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
EP3455262A4 (en) 2016-05-13 2020-04-08 The General Hospital Corporation ANTAGONISTIC ANTI-TUMOR NECROSE FACTOR RECEPTOR SUPER FAMILY ANTIBODIES
WO2018031400A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
SG10201912565QA (en) 2016-09-29 2020-02-27 Amgen Inc Low-viscosity antigen binding proteins and methods of making them
JP7054209B2 (ja) 2016-11-21 2022-04-13 国立研究開発法人医薬基盤・健康・栄養研究所 エピトープ均質化抗体パネル、ならびにその作製方法および利用
CN110291108A (zh) 2016-12-19 2019-09-27 格兰马克药品股份有限公司 新型tnfr激动剂及其用途
EP3707163A4 (en) 2017-11-09 2021-08-18 The General Hospital Corporation POLYPEPTIDES ANTAGONISTS OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY
US20210340268A1 (en) 2018-08-20 2021-11-04 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides

Also Published As

Publication number Publication date
EP2953634A1 (en) 2015-12-16
JP6367836B2 (ja) 2018-08-01
PT2953634T (pt) 2021-09-02
US9821010B2 (en) 2017-11-21
US20200368282A1 (en) 2020-11-26
US11844814B2 (en) 2023-12-19
JP2016509009A (ja) 2016-03-24
JP2018168183A (ja) 2018-11-01
HRP20211353T1 (hr) 2021-11-26
JP2021050225A (ja) 2021-04-01
US20180161370A1 (en) 2018-06-14
EP2953634B1 (en) 2021-05-26
US10765700B2 (en) 2020-09-08
WO2014124134A1 (en) 2014-08-14
US20150366909A1 (en) 2015-12-24
JP2023040077A (ja) 2023-03-22
EP2953634A4 (en) 2016-08-17
JP2025166059A (ja) 2025-11-05
DK2953634T3 (da) 2021-08-30
PL2953634T3 (pl) 2021-11-22
US20240216431A1 (en) 2024-07-04
JP6808688B2 (ja) 2021-01-06
EP3936137A1 (en) 2022-01-12
JP7257374B2 (ja) 2023-04-13

Similar Documents

Publication Publication Date Title
ES2885423T3 (es) Procedimientos para la expansión o el empobrecimiento de células T reguladoras
Huff et al. The evolving role of CD8+ CD28− immunosenescent T cells in cancer immunology
WO2021053667A2 (en) Combination cancer therapy and cytokine control therapy for cancer treatment
BR112019020214A2 (pt) substituição do pré-condicionamento citotóxico antes da imunoterapia celular
US20170058026A1 (en) Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways
CN104853776A (zh) 免疫应答的增强
US11986538B2 (en) Immunoswitch nanoparticles for reprogrammed T cell responses
CN113574172A (zh) 用于免疫疗法的组合物和方法
JP7278296B2 (ja) Ａｌｌｏ－ＨＣＴを受けた患者の血液悪性腫瘍の治療に使用するためのＧＭ－ＣＳＦまたはＧＭ－ＣＳＦ受容体のリガンド
HK40065666A (en) Methods for expansion or depletion of t-regulatory cells
EP4031655A2 (en) Combination cancer therapy and cytokine control therapy for cancer treatment
KR20240099228A (ko) 조작된 nk 세포 및 이의 용도
JP2024538707A (ja) Ｉｌ－２プロドラッグ
KR20250054790A (ko) 키메라 항원 수용체 도메인
WO2025202284A1 (en) Glp-1r antagonists for the treatment of cancer